Consumer staples stocks are solid insurance policies in frothy markets ripe for corrections. Surprisingly, the sector hasn’t played its shielding role over the past six months as it tumbled 10.5%. This drawdown was particularly disappointing since the S&P 500 held its ground. Some companies can buck this trend, but the odds aren’t great for the ones we’re analyzing today. On that note, here are three consumer stocks that may face trouble. Lamb Weston (LW) Market Cap: $7.60 billion Best known for its Grown in Idaho brand, Lamb Weston (NYSE:LW) produces and distributes potato products such as frozen french fries and mashed potatoes. Why Are We Wary of LW? Projected sales are flat for the next 12 months, implying demand will slow from its three-year trend Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 5 percentage points Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 0% for the last two years Lamb Weston’s stock price of $53.49 implies a valuation ratio of 15.7x forward P/E. Check out our free in-depth research report to learn more about why LW doesn’t pass our bar. Nature's Sunshine (NATR) Market Cap: $272.9 million Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Why Are We Hesitant About NATR? Sales were flat over the last three years, indicating it's failed to expand its business Smaller revenue base of $456.6 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy Earnings per share fell by 20.6% annually over the last three years while its revenue was flat, showing each sale was less profitable Nature's Sunshine is trading at $14.77 per share, or 19.2x forward P/E. Read our free research report to see why you should think twice about including NATR in your portfolio, it’s free. BeautyHealth (SKIN) Market Cap: $219.2 million Operating in the emerging beauty health category, the appropriately named BeautyHealth (NASDAQ:SKIN) is a skincare company best known for its Hydrafacial product that cleanses and hydrates skin. Why Are We Out on SKIN? Annual revenue growth of 3.8% over the last three years was below our standards for the consumer staples sector Historical operating losses point to an inefficient cost structure High net-debt-to-EBITDA ratio of 10× increases the risk of forced asset sales or dilutive financing if operational performance weakens At $1.80 per share, BeautyHealth trades at 13.7x forward EV-to-EBITDA. If you’re considering SKIN for your portfolio, see our FREE research report to learn more. Story Continues Stocks We Like More The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
3 Consumer Stocks with Mounting Challenges
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...